Security key
28036F105
Edgewise Therapeutics, Inc. - Common Stock, $0.0001 par value per share (EWTX)
CUSIP: 28036F105
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Total 13F shares
- 119,194,438
- Total 13F value
- $4,822,487,808
- Share change
- +498,622
- Put/Call ratio
- 49%
- SEC-reported price per share
- $40.63
- Number of holders
- 226
- Value change
- +$51,387,100
- Number of buys
- 123
- Number of sells
- 100
- Shares outstanding
- 107,531,105
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
226
Top holders
10
EWTX full security history
Ownership snapshot
Full 13F holder table
Edgewise Therapeutics, Inc. SEC filings
Edgewise Therapeutics, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of EWTX - Edgewise Therapeutics, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
Paradigm Biocapital Advis...
Comparable rows
15/15
Latest evidence
30 Jun 2026
13F
13D/G
3/4/5
Lead comparable stake: 14%
13D/G row: ORBIMED ADVISORS LLC
Showing 1-6 of 15 holder rows.
Quick read
ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 14%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORBIMED ADVISORS LLC's linked filing trail.
Comparable ownership
Top 5
ORBIMED ADVISORS LLC
14%
Paradigm Biocapital Advisors LP
9.5%
RA CAPITAL MANAGEMENT, L.P.
7.8%
BlackRock, Inc.
5.5%
Janus Henderson Group Ltd.
5.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
13D/G
3/4/5
Company · Director, 10%+ Owner
|
14%
from 13D/G
|
$488,832,498
15,518,492 shares
|
— | 31 Mar 2026 |
| Paradigm Biocapital Advisors LP |
13D/G
13F
Company
|
9.5%
|
$493,917,249
10,215,455 shares
|
+$177,649,746 | 30 Jun 2026 |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
13F
Company
|
7.8%
|
$405,788,496
8,392,730 shares
|
-$98,426,433 | 30 Jun 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
5.5%
from 13D/G
|
$203,899,220
6,472,991 shares
|
— | 31 Mar 2026 |
| Janus Henderson Group Ltd. |
13D/G
13F
JANUS HENDERSON GROUP PLC · Company
|
5.5%
|
$197,165,481
5,915,556 shares
|
+$31,204,379 | 31 Mar 2026 |
| FMR LLC |
13D/G
13F
Company
|
5.1%
|
$265,399,677
5,489,135 shares
|
$0 | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
226
Shares
119,194,438
Rows available
226
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
212
Q2 2026 holders
226
Holder diff
14
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|